The new compound, called GSK-299423, works against antibiotic- resistant bugs including strains of Staphylococcus aureus and gram-negative microbes such as E. coli, the statement said. While futures sales for an early-stage molecule are difficult to predict, two of the top-selling branded antibiotics, New York-based Pfizer Inc.’s Zyvox and Cubicin, from Lexington, Massachusetts-based Cubist Pharmaceuticals Inc., generated $1.1 billion and $538 million in sales last year, respectively.
via bloomberg.com
No comments:
Post a Comment